select a format

Single User License
USD 1500 INR 96555
Site License
USD 3000 INR 193110
Corporate User License
USD 4500 INR 289665

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Xencor, Inc.-Product Pipeline Review-2015

Xencor, Inc.-Product Pipeline Review-2015


  • Products Id :- GMDHC07423CDB
  • |
  • Pages: 40
  • |
  • August 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Xencor, Inc.-Product Pipeline Review-2015

Summary

Global Markets Direct's, 'Xencor, Inc.-Product Pipeline Review-2015', provides an overview of the Xencor, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Xencor, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides brief overview of Xencor, Inc. including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Xencor, Inc.'s human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Xencor, Inc.'s pipeline products

Reasons To Buy

Evaluate Xencor, Inc.'s strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Xencor, Inc. in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Xencor, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Xencor, Inc. and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Xencor, Inc.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Xencor, Inc. and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Xencor, Inc. Snapshot 5

Xencor, Inc. Overview 5

Key Information 5

Key Facts 5

Xencor, Inc.-Research and Development Overview 6

Key Therapeutic Areas 6

Xencor, Inc.-Pipeline Review 9

Pipeline Products by Stage of Development 9

Pipeline Products-Monotherapy 10

Pipeline Products-Partnered Products 11

Partnered Products/Combination Treatment Modalities 12

Pipeline Products-Out-Licensed Products 13

Out-Licensed Products/Combination Treatment Modalities 14

Xencor, Inc.-Pipeline Products Glance 15

Xencor, Inc.-Clinical Stage Pipeline Products 15

Phase I Products/Combination Treatment Modalities 15

Xencor, Inc.-Early Stage Pipeline Products 16

Preclinical Products/Combination Treatment Modalities 16

Discovery Products/Combination Treatment Modalities 17

Xencor, Inc.-Drug Profiles 18

XmAb-5871 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

Monoclonal Antibody 2 for Oncology 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

Monoclonal Antibody for Oncology 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

XmAb-7195 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

XENP-1138 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

XmAb-13243 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

XmAb-13551 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

XmAb-13676 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

XmAb-13677 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

XmAb-14045 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

Xtend-TNF 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

Monoclonal Antibody to Agonize CD32b for Undisclosed Indication 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

Xencor, Inc.-Pipeline Analysis 31

Xencor, Inc.-Pipeline Products by Target 31

Xencor, Inc.-Pipeline Products by Route of Administration 32

Xencor, Inc.-Pipeline Products by Molecule Type 33

Xencor, Inc.-Pipeline Products by Mechanism of Action 34

Xencor, Inc.-Recent Pipeline Updates 35

Xencor, Inc.-Dormant Projects 37

Xencor, Inc.-Locations And Subsidiaries 38

Head Office 38

Appendix 39

Methodology 39

Coverage 39

Secondary Research 39

Primary Research 39

Expert Panel Validation 39

Contact Us 39

Disclaimer 40

List of Tables

Xencor, Inc., Key Information 5

Xencor, Inc., Key Facts 5

Xencor, Inc.-Pipeline by Indication, 2015 8

Xencor, Inc.-Pipeline by Stage of Development, 2015 9

Xencor, Inc.-Monotherapy Products in Pipeline, 2015 10

Xencor, Inc.-Partnered Products in Pipeline, 2015 11

Xencor, Inc.-Partnered Products/ Combination Treatment Modalities, 2015 12

Xencor, Inc.-Out-Licensed Products in Pipeline, 2015 13

Xencor, Inc.-Out-Licensed Products/ Combination Treatment Modalities, 2015 14

Xencor, Inc.-Phase I, 2015 15

Xencor, Inc.-Preclinical, 2015 16

Xencor, Inc.-Discovery, 2015 17

Xencor, Inc.-Pipeline by Target, 2015 31

Xencor, Inc.-Pipeline by Route of Administration, 2015 32

Xencor, Inc.-Pipeline by Molecule Type, 2015 33

Xencor, Inc.-Pipeline Products by Mechanism of Action, 2015 34

Xencor, Inc.-Recent Pipeline Updates, 2015 35

Xencor, Inc.-Dormant Developmental Projects,2015 37

List of Figures

Xencor, Inc.-Pipeline by Top 10 Indication, 2015 7

Xencor, Inc.-Pipeline by Stage of Development, 2015 9

Xencor, Inc.-Monotherapy Products in Pipeline, 2015 10

Xencor, Inc.-Partnered Products in Pipeline, 2015 11

Xencor, Inc.-Out-Licensed Products in Pipeline, 2015 13

Xencor, Inc.-Pipeline by Top 10 Target, 2015 31

Xencor, Inc.-Pipeline by Top 10 Route of Administration, 2015 32

Xencor, Inc.-Pipeline by Top 10 Molecule Type, 2015 33

Xencor, Inc.-Pipeline Products by Top 10 Mechanism of Action, 2015 34

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Current R&D Portfolio of Xencor, Inc.; Xencor, Inc. - Key Therapeutics; Xencor, Inc. - Pipeline Overview and Promising Molecules; Xencor, Inc. - News; Xencor, Inc. - Latest Updates; Xencor, Inc. - Pipeline; Xencor, Inc. - Discontinued/Dormant Projects


Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com